About Corlieve Therapeutics
Corlieve Therapeutics is a company based in Paris (France) founded in 2019 by Valerie Crepel, Christophe Mulle, and Richard Porter was acquired by UniQure in June 2021. Corlieve Therapeutics offers products and services including Domain Registration, Web Hosting, Email Hosting, and VPS. Corlieve Therapeutics operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Paris, France
- Founders Valerie Crepel, Christophe Mulle, Richard Porter
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Corlieve Therapeutics
Corlieve Therapeutics offers a comprehensive portfolio of products and services, including Domain Registration, Web Hosting, Email Hosting, and VPS.
Service for reserving and managing domain names online.
Platform for activating and using web hosting packages.
Solution for email management and hosting needs.
Virtual server for advanced hosting and customization.
Funding Insights of Corlieve Therapeutics
Investors in Corlieve Therapeutics
Corlieve Therapeutics has secured backing from 4 investors, including venture fund investors. Prominent investors backing the company include UniQure, Idinvest Partners and Kurma Partners.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Biotech startups are funded through venture capital in life sciences.
|
Locked | Locked | Locked | |
|
Equity investments are provided to low and middle market companies.
|
Locked | Locked | Locked | |
|
Venture capital is invested in innovative drug development companies.
|
Locked | Locked | Locked |
Investor details for Corlieve Therapeutics
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Corlieve Therapeutics
Investment portfolio details for Corlieve Therapeutics
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Corlieve Therapeutics
Detailed financials for Corlieve Therapeutics
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Corlieve Therapeutics Comparisons
Peer comparison for Corlieve Therapeutics
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Corlieve Therapeutics
Corlieve Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| Locked | Locked | Locked |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| Locked | Locked | Locked |
RNA interference-based therapeutics are developed for multiple disorders.
|
|
| Locked | Locked | Locked |
A biopharmaceutical company accelerating innovative mental health treatments.
|
|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
Detailed competitors of Corlieve Therapeutics
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Corlieve Therapeutics
Complete news archive for Corlieve Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Corlieve Therapeutics
Corlieve Therapeutics was founded in 2019 and raised its 1st funding round 1 year after it was founded.
Corlieve Therapeutics is headquartered in Paris, France.
Richard Porter is the current CEO of Corlieve Therapeutics. They have also founded this company.
Corlieve Therapeutics was founded in 2019 in Paris, France, within the biotechnology sector. Focus is placed on developing therapeutic solutions for neurological disorders through advanced drug delivery technologies. Gene therapy methods, supported by an AAV gene delivery platform, are utilized to address drug-resistant temporal lobe epilepsy. Operations center on innovative treatments for unmet medical needs in neurology.
Corlieve Therapeutics's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
Corlieve Therapeutics offers Domain Registration, Web Hosting, Email Hosting, and VPS.
Corlieve Therapeutics has 4 investors. Key investors include UniQure, Idinvest Partners, Kurma Partners, and Pureos Bioventures.